Detaljert guide kommer snart
Vi jobber med en omfattende veiledning for Startup Valuation Calculator. Kom tilbake snart for trinnvise forklaringer, formler, eksempler fra virkeligheten og eksperttips.
Startup valuation is the process of estimating the current worth of a pre-profitability or early-stage company. Unlike mature businesses that can be valued using discounted cash flows or earnings multiples, startups often lack stable revenue, profit, or even customers — making their valuation inherently uncertain and largely based on future potential, market size, team quality, and comparable transactions. Several valuation methods are used for early-stage companies. The Comparable Transactions Method uses recent funding rounds for similar companies (same stage, industry, geography) as benchmarks. The Revenue Multiple Method applies an industry-standard multiple to current or projected revenue (common for SaaS: 5-15x ARR at Series A). The Berkus Method assigns value to five startup success factors (sound idea, prototype, quality management team, strategic relationships, and product rollout or sales) — each worth up to $500,000, for a maximum pre-revenue valuation of $2.5M. The Scorecard Method adjusts a median comparable valuation by scoring the startup against the comparison group on team, opportunity, product, competitive environment, marketing, and need for additional investment. The VC Method back-calculates a current valuation from the expected terminal value at exit, discounted by the VC's required rate of return. For revenue-generating startups, the most common valuation method is the revenue multiple approach. SaaS companies are typically valued at 4-12x ARR depending on growth rate, net revenue retention, gross margin, and market size. Faster-growing companies command higher multiples: a SaaS company growing 150% year-over-year might trade at 12-15x ARR, while one growing 30% might trade at 4-5x ARR. Public market SaaS valuations (which serve as the ceiling for private valuations) have ranged from 4x to 25x revenue over the 2018-2024 period, peaking in late 2021 at extreme multiples driven by ZIRP conditions. Pre-money vs. post-money valuation is a critical distinction in startup finance. Pre-money valuation is the agreed company value before new investment is added. Post-money valuation is pre-money valuation plus the new investment amount. If an investor puts $5M into a company valued at $15M pre-money, the post-money valuation is $20M and the investor owns 25% ($5M / $20M). Founders must understand this distinction because dilution calculations depend on post-money valuation, not pre-money.
Startup Valuation Calculation: Step 1: Determine the stage and primary valuation method: Berkus/Scorecard for pre-revenue, Revenue Multiple for early-revenue startups, or VC Method for later-stage projections. Step 2: For Revenue Multiple: identify the current ARR and the appropriate multiple based on growth rate (100%+ growth = 10-15x, 50-100% = 7-10x, 30-50% = 5-7x, <30% = 4-5x) and adjust for gross margin and net revenue retention. Step 3: Research comparable transactions using PitchBook, Crunchbase, or AngelList data for similar companies at the same stage, industry, and geography. Step 4: Apply the VC Method: estimate exit value in 5-7 years (comparable exit multiples x projected ARR at exit), apply VC required return (typically 10x for seed, 5x for Series A), and back-calculate current valuation. Step 5: Triangulate across all methods to establish a valuation range — the final pre-money valuation will be negotiated within this range based on the relative leverage of founder vs. investor. Step 6: Calculate post-money valuation: Pre-Money + Investment Amount. Step 7: Calculate investor ownership: Investment Amount / Post-Money Valuation. Each step builds on the previous, combining the component calculations into a comprehensive startup valuation result. The formula captures the mathematical relationships governing startup valuation behavior.
- 1Determine the stage and primary valuation method: Berkus/Scorecard for pre-revenue, Revenue Multiple for early-revenue startups, or VC Method for later-stage projections.
- 2For Revenue Multiple: identify the current ARR and the appropriate multiple based on growth rate (100%+ growth = 10-15x, 50-100% = 7-10x, 30-50% = 5-7x, <30% = 4-5x) and adjust for gross margin and net revenue retention.
- 3Research comparable transactions using PitchBook, Crunchbase, or AngelList data for similar companies at the same stage, industry, and geography.
- 4Apply the VC Method: estimate exit value in 5-7 years (comparable exit multiples x projected ARR at exit), apply VC required return (typically 10x for seed, 5x for Series A), and back-calculate current valuation.
- 5Triangulate across all methods to establish a valuation range — the final pre-money valuation will be negotiated within this range based on the relative leverage of founder vs. investor.
- 6Calculate post-money valuation: Pre-Money + Investment Amount.
- 7Calculate investor ownership: Investment Amount / Post-Money Valuation.
Scorecard weights: Team 30%, Opportunity 25%, Product 15%, Sales 10%, Other 20%.
The Scorecard Method adjusts a median comparable valuation by scoring the startup against the comparison group on weighted criteria. Weighted score: (1.30 x 30%) + (1.25 x 25%) + (1.10 x 15%) + (0.80 x 10%) + (1.0 x 20%) = 0.39 + 0.3125 + 0.165 + 0.08 + 0.20 = 1.1475. Applying to the $3M median: $3M x 1.1475 = $3.44M, typically rounded to $3.5M in negotiation. The outstanding team and large market opportunity drive the above-average valuation, while the below-average sales/partnerships performance (early stage, pre-revenue) moderates the total. This method is widely used by seed investors for pre-revenue companies where revenue multiples are inapplicable.
High growth (180% YoY) + strong NRR (120%) + good margins (78%) justify upper end of the range.
This SaaS startup at $2.1M ARR growing 180% year-over-year with 120% net revenue retention (existing customers expand their contracts) commands a premium multiple. The 10-15x ARR range yields a valuation of $21M-$31.5M. The strong net revenue retention (120%) is particularly valuable — it means the business would grow even with zero new customer acquisition, creating compounding revenue. Combined with 180% growth and healthy 78% gross margins, this company justifies the upper end of the comparable range. A $25M pre-money valuation is a reasonable negotiated outcome, representing approximately 12x ARR. With a $5M investment, post-money would be $30M and investor ownership 16.7%.
VC Method: Exit value $240M / 10x required return = $24M post-money; minus $3M investment = $21M pre-money at full certainty. Risk-adjusted for 20% success probability: $4.2M pre-money.
The VC Method back-calculates current valuation from the expected terminal value. If this company reaches $30M ARR in 5 years and exits at 8x ARR, the terminal value is $240M. A VC requiring a 10x return on a $3M investment needs to own $30M / $240M = 12.5% at exit. To own 12.5% post-seed at $3M investment, post-money must be $3M / 0.125 = $24M, implying a $21M pre-money. However, most VCs apply a probability adjustment — if there is only a 20% chance this scenario plays out, the expected value is $240M x 20% = $48M at exit, adjusting the calculation: $48M / 10 / 0.125 = $38.4M required ownership, not 12.5% but 37.5% — leading to a lower pre-money of ~$5M. Seed investors typically apply these steep probability adjustments, explaining why even companies with $240M exit potential receive pre-money valuations of $4-8M at seed.
85% growth justifies 7.5x ARR = $90M; strong NRR (115%) supports this multiple vs lower-NRR peers.
At $12M ARR with 85% year-over-year growth, this enterprise SaaS company is in the median range for Series B multiples. Public SaaS companies at similar growth rates trade at 7-9x revenue on public markets; private companies receive a slight premium for faster growth potential but are discounted for illiquidity. The 115% NRR (net revenue retention above 100% means existing customers are expanding contracts) is a crucial quality indicator that justifies the mid-to-upper range of the multiple. A $90M pre-money valuation at 7.5x ARR is fair for this profile. If the company were growing 150%+ or had 130%+ NRR, it could command 10-12x ARR. With a $25M Series B investment at $90M pre-money, post-money is $115M and Series B investor ownership is 21.7%.
Preparing for fundraising conversations with investors, representing an important application area for the Startup Valuation in professional and analytical contexts where accurate startup valuation calculations directly support informed decision-making, strategic planning, and performance optimization
Term sheet negotiation: understanding what proposed terms mean for founder ownership, representing an important application area for the Startup Valuation in professional and analytical contexts where accurate startup valuation calculations directly support informed decision-making, strategic planning, and performance optimization
Employee equity grant pricing and option exercise decisions, representing an important application area for the Startup Valuation in professional and analytical contexts where accurate startup valuation calculations directly support informed decision-making, strategic planning, and performance optimization
Acquihire and acquisition valuation negotiations, representing an important application area for the Startup Valuation in professional and analytical contexts where accurate startup valuation calculations directly support informed decision-making, strategic planning, and performance optimization
Investor reporting and portfolio company valuation for fund reporting, representing an important application area for the Startup Valuation in professional and analytical contexts where accurate startup valuation calculations directly support informed decision-making, strategic planning, and performance optimization
{'case': 'Biotech and Hard Tech Valuations', 'description': 'Life science and deep tech startups are often valued on pipeline milestones rather than revenue multiples. Biotech valuations use probability-adjusted net present value (rNPV), accounting for clinical trial success probabilities at each phase. A drug in Phase 2 trials might be valued at $100M even with zero revenue based on the probability-adjusted commercial potential of the underlying molecule.'}
{'case': 'International Startup Valuations', 'description': 'Startup valuations in non-US markets typically apply a discount of 20-40% versus US comparables due to smaller exit markets, thinner venture ecosystems, and higher execution risk. However, startups from top international ecosystems (Israel, UK, India for tech) increasingly command near-US valuations when backed by global investors or targeting global markets.'}
{'case': 'Dual-Class Share Structures', 'description': 'Founders at high-growth companies sometimes negotiate dual-class share structures that give founder shares 10x or more the voting rights of investor shares. This allows founders to maintain control even as they raise multiple large rounds of capital and their ownership percentage falls below 50%. Investors in such structures accept reduced governance rights in exchange for participating in exceptional companies.'}
| Stage | Median Pre-Money | Median Round Size | Typical Multiple |
|---|---|---|---|
| Pre-Seed / Angel | $3M-$8M | $250K-$1M | N/A (pre-revenue) |
| Seed | $8M-$15M | $1M-$4M | N/A or 10-20x MRR |
| Series A | $20M-$40M | $5M-$15M | 8-15x ARR |
| Series B | $60M-$120M | $20M-$50M | 6-10x ARR |
| Series C | $150M-$500M | $50M-$150M | 5-8x ARR |
| Late Stage / Pre-IPO | $500M+ | $100M+ | 4-8x ARR |
What are the most common startup valuation methods?
The most common valuation methods for startups vary by stage. For pre-revenue startups: the Berkus Method (qualitative milestones, max $2.5M pre-money valuation), the Scorecard Method (compares startup to peers on weighted criteria), and the Risk Factor Summation Method (adjusts a base valuation for 12 categories of risk). For revenue-generating startups: the Revenue Multiple Method (current ARR x industry multiple), the Comparable Transactions Method (recent similar funding rounds), and the Discounted Cash Flow Method (for more mature companies with predictable revenue). The VC Method is used across stages to back-calculate from expected exit value. Most sophisticated investors use 2-3 methods to triangulate a range before negotiating.
What is pre-money vs. post-money valuation?
Pre-money valuation is the agreed value of the company before new investment capital is added. Post-money valuation is pre-money valuation plus the new investment amount. If a company has a $10M pre-money valuation and receives a $2M investment, the post-money valuation is $12M. The investor who contributed $2M owns $2M / $12M = 16.7% of the company post-investment. The founders and existing shareholders own the remaining 83.3%. This distinction is critical because founders can be fooled by a high-seeming pre-money valuation without realizing a large investment in that context results in significant dilution. Always calculate ownership percentage using post-money valuation, not pre-money.
What revenue multiples are used for SaaS company valuations?
SaaS revenue multiples vary significantly based on growth rate, net revenue retention, gross margin, market size, and prevailing market conditions. In 2023-2024, public SaaS multiples ranged from 4x to 15x ARR, with the median around 7-8x for companies growing 20-40%. Private company multiples typically sit at or slightly above comparable public multiples due to growth potential, but discounted for illiquidity. Growth rate is the primary driver: companies growing 100%+ year-over-year may command 12-20x ARR; those growing 30-50% typically get 5-8x. Net revenue retention above 120% (strong expansion revenue from existing customers) commands a significant premium — investors apply a 1-2x multiple premium for every 10 percentage points of NRR above 100%.
How does market size affect startup valuation?
Market size (Total Addressable Market, or TAM) significantly influences early-stage startup valuations because investors are pricing future potential, not current reality. A startup solving a problem in a $100B market can potentially become a $1B+ company; the same startup in a $500M market has much lower upside. Investors apply a market size discount when TAM is insufficient to support the target exit valuation they need. For a VC fund needing 10x returns, a $10M investment needs to grow to $100M in value — requiring the startup to be worth $100M+ at exit. If the total market can only support $50M peak revenue, the exit value may never reach $100M, making the investment unattractive regardless of execution quality. VCs typically want to invest in companies targeting markets of $1B+ to have enough room for a fund-returning outcome.
What is a down round and when does it happen?
A down round occurs when a startup raises new capital at a pre-money valuation lower than its previous round's post-money valuation — meaning the company's estimated value has declined between funding rounds. Down rounds are damaging for founders and existing investors because anti-dilution provisions in preferred stock (particularly full ratchet provisions) can cause extreme dilution of common stockholders. They signal to the market that the company has underperformed its projections and makes future recruiting and customer acquisition harder. Down rounds became more common in 2022-2024 as many companies that raised at peak 2021 valuations failed to grow into those valuations when market conditions tightened. Down rounds are sometimes necessary and are preferable to running out of money — a lower valuation down round is better than a shutdown.
How does the YC Standard SAFE affect startup valuations?
Y Combinator's Simple Agreement for Future Equity (SAFE) is the most common instrument for pre-seed and seed funding. The YC Standard SAFE converts into equity at the next priced round at either the valuation cap (maximum valuation at which the SAFE converts) or a discount (typically 15-20% off the next round price), whichever is more favorable to the SAFE investor. The valuation cap effectively sets a ceiling on the conversion price, creating a valuation implied by the SAFE terms even though no explicit valuation is negotiated. A $3M SAFE cap means the investor effectively agreed to buy equity at a valuation no higher than $3M — if the Series A is at $20M pre-money, the SAFE investor converts at $3M, owning significantly more than an investor who paid Series A prices. The valuation cap thus determines SAFE investor economics without setting a formal current valuation.
How do you value a startup with no revenue?
Pre-revenue startup valuation is more art than science, but structured methods exist. The Berkus Method assigns value to five elements: sound idea ($500K max), prototype ($500K), quality management team ($500K), strategic relationships ($500K), and product rollout or sales ($500K) — for a pre-revenue ceiling of $2.5M. The Scorecard Method benchmarks against recent comparable seed transactions (typically $2-10M pre-money for B2B SaaS pre-revenue) and adjusts for relative team, market, and product quality. In practice, pre-revenue valuations are primarily determined by: the quality and track record of the founding team, the uniqueness and defensibility of the technology or approach, the size and growth rate of the target market, and the current enthusiasm level of the investor community for the specific category.
Pro Tips
Startup valuations are negotiated outcomes, not calculated truths. Use multiple methods (comparable transactions, revenue multiples, DCF, VC method) to triangulate a range, then negotiate based on the strength of your traction, team, and market.
Visste du?
According to PitchBook data, the median Series A pre-money valuation in the US was approximately $25M in 2023, down from a peak of $45M in 2021 — illustrating how dramatically macro conditions (interest rates, public market valuations) affect startup valuations.